Vaccine composition for vaccinating dogs against canine infectious respiratory disease(cird)

Abstract

A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.

1 . A method of vaccinating a dog against canine infectious respiratory disease (CIRD), the method comprising administering to the dog a vaccine composition comprising an agent capable of raising an immune response against  Streptococcus equi  sub species  zooepidemicus  ( S. zooepidemicus ) in a dog. 
     
     
         2 . A method of treating CIRD in a dog, the method comprising administering to the dog a vaccine composition comprising an agent capable of raising an immune response against  S. zooepidemicus  in a dog. 
     
     
         3 . A method of stimulating an immune response against  S. zooepidemicus  in a dog, the method comprising administering to the dog an agent capable of raising an immune response against  S. zooepidemicus  in a dog. 
     
     
         4 . A method according to any of  claims 1  to  3  wherein the agent capable of raising an immune response against  Streptococcus equi  sub species  zooepidemicus  ( S. zooepidemicus ) in a dog comprises an agent selected from the group consisting of inactivated or attenuated  S. zooepidemicus , an immunogenic fragment of  S. zooepidemicus  or a derivative thereof, and a nucleic acid molecule encoding said fragment or said derivative. 
     
     
         5 . The method according to  claim 1  or  2  further comprising administering to the dog an agent capable of raising an immune response against  Mycoplasma  cynos ( M. cynos ) in a dog. 
     
     
         6 . The method according to  claim 5  wherein the agent capable of raising an immune response against  M. cynos  in a dog comprises an agent selected from the group consisting of inactivated or attenuated M. cynos, an immunogenic fragment of  M. cynos  or a derivative thereof, and a nucleic acid molecule encoding said fraction or said derivative. 
     
     
         7 . The method according to  claim 1  or  2  further comprising administering to the dog an agent capable of raising an immune response against a  Chlamydophila  in a dog. 
     
     
         8 . The method according to  claim 7  wherein the agent capable of raising an immune response in a dog against a  Chlamydophila  comprises an agent selected from the group consisting of inactivated or attenuated  Chlamydophila abortus, Chlamydophila psittaci, Chlamydophila felis, Chlamydia muridarum, Chlamydia pecorum, Chlamydia pneumoniae, Chlamydia suis  and  Chlamydia trachomatis , an immunogenic fragment thereof or a derivative thereof, and a nucleic acid molecule encoding said fraction or said derivative. 
     
     
         9 . The method according to  claim 1  or  2  further comprising administering to the dog any one or more of:
 an agent capable of raising an immune response in a dog against canine respiratory coronavirus (CRCV);   an agent capable of raising an immune response in a dog against canine parainfluenzavirus (CPIV);   an agent capable of raising an immune response in a dog against canine adenovirus type 2 (CAV-2);   an agent capable of raising an immune response in a dog against canine herpesvirus (CHV); and   an agent capable of raising an immune response in a dog against  Bordetella bronchiseptica  ( B. bronchiseptica ).   
     
     
         10 . The method according to  claim 9  wherein the agent capable of raising an immune response in a dog against CRCV comprises an agent selected from the group consisting of inactivated or attenuated CRCV, an immunogenic fragment thereof, and a nucleic acid molecule encoding said immunogenic fraction. 
     
     
         11 . The method according to  claim 10  wherein the immunogenic fragment of CRCV comprises the Spike protein or the hemagglutinin-esterase (HE) protein, or an immunogenic portion of the Spike or HE protein. 
     
     
         12 . The method according to  claim 9  wherein the agent capable of raising an immune response in a dog against CPIV comprises an agent selected from the group consisting of inactivated or attenuated CPIV, an immunogenic fragment thereof, and a nucleic acid molecule encoding said immunogenic fraction. 
     
     
         13 . The method according to  claim 9  wherein the agent capable of raising an immune response in a dog against CAV-2 comprises an agent selected from the group consisting of inactivated or attenuated CAV-2, an immunogenic fragment thereof, and a nucleic acid encoding said immunogenic fraction. 
     
     
         14 . The method according to  claim 9  wherein the agent capable of raising an immune response in a dog against CHV comprises an agent selected from the group consisting of inactivated or attenuated CHV, an immunogenic fragment thereof, and a nucleic acid molecule encoding said immunogenic fraction. 
     
     
         15 . The method according to  claim 9  wherein the agent capable of raising an immune response in a dog against  B. bronchiseptica  comprises an agent selected from the group consisting of inactivated or attenuated  B. bronchiseptica , an immunogenic fragment thereof, and a nucleic acid molecule encoding said immunogenic fraction. 
     
     
         16 . A method of determining whether a dog has or is susceptible to CIRD, the method comprising:
 (a) obtaining a suitable sample from the dog; and   (b) identifying  S. zooepidemicus , or an antibody to  S. zooepidemicus , in the sample.   
     
     
         17 . The method according to  claim 16  wherein the  S. zooepidemicus  is identified using an antibody. 
     
     
         18 . The method according to  claim 16  wherein the  S. zooepidemicus  is identified using a nucleic acid molecule. 
     
     
         19 . The method according to  claim 16  wherein the anti-S. zooepidemicus antibody is identified using  S. zooepidemicus  or an antigenic portion thereof. 
     
     
         20 . The method according to  claim 16  wherein the sample is an antibody-containing sample such as serum, saliva, tracheal wash or branchiolar lavage.